Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11

Given the controversies in the prognostic value of KIT mutations and optimal thresholds and time points of MRD monitoring for AML with CBFB-MYH11 , we retrospectively evaluated 88 patients who underwent allogeneic hematopoietic stem cell transplantation (Allo-HSCT, n  = 60) or autologous HSCT (Auto-...

Full description

Saved in:
Bibliographic Details
Published inBone marrow transplantation (Basingstoke) Vol. 56; no. 11; pp. 2682 - 2689
Main Authors Cho, Byung-Sik, Min, Gi-June, Park, Sung-Soo, Park, Silvia, Jeon, Young-Woo, Shin, Seung-Hwan, Yahng, Seung-Ah, Yoon, Jae-Ho, Lee, Sung-Eun, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Kim, Dong-Wook, Lee, Jong Wook, Kim, Myungshin, Kim, Yonggoo, Kim, Hee-Je
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.11.2021
Nature Publishing Group
Subjects
45/23
45/77
631/208/69
631/67/1990/283/1897
692/308/575
692/699/1541/1990/283/1897
Acute myeloid leukemia
Assessments
Autografts
Cell Biology
Core Binding Factor beta Subunit - genetics
Gene mutations
Health aspects
Hematology
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Internal Medicine
Leukemia
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - therapy
Medicine
Medicine & Public Health
Monitoring
Multivariate analysis
Mutation
Myeloid leukemia
Myosin Heavy Chains - genetics
Neoplasm, Residual - diagnosis
Neoplasm, Residual - genetics
Prognosis
Public Health
Retrospective Studies
Stem cell transplantation
Stem Cells
Survival
Thresholds
Transplantation
Transplants & implants
South Korea
Online AccessGet full text
ISSN0268-3369
1476-5365
1476-5365
DOI10.1038/s41409-021-01384-w

Cover

Abstract Given the controversies in the prognostic value of KIT mutations and optimal thresholds and time points of MRD monitoring for AML with CBFB-MYH11 , we retrospectively evaluated 88 patients who underwent allogeneic hematopoietic stem cell transplantation (Allo-HSCT, n  = 60) or autologous HSCT (Auto-HSCT, n  = 28). The D816V KIT mutation was significantly associated with post-transplant relapse, contrasting with other types of mutations in KIT . Pre- and post-transplant (3 months after transplant) CBFB-MYH11 MRD assessments were useful in predicting post-transplant relapse and poor survival. The optimal threshold was determined as a 2 log reduction at both time points. In multivariate analysis, the D816V KIT mutation and CBFB-MYH11 MRD assessments were independently associated with post-transplant relapse and survival. Stratification by D816V KIT and pre-transplant CBFB-MYH11 MRD status further distinguished the risk of relapse and survival. Auto-HSCT was superior to Allo-HSCT in MRD negative patients without D816V KIT , while Allo-HSCT trended to be superior to Auto-HSCT in patients with MRD positivity or the D816V KIT mutation. In conclusion, this study demonstrated the differentiated prognostic value of the D816V KIT mutation in AML with CBFB-MYH11 and clarified optimal time points and thresholds for CBFB-MYH11 MRD monitoring in the setting of HSCT.
AbstractList Given the controversies in the prognostic value of KIT mutations and optimal thresholds and time points of MRD monitoring for AML with CBFB-MYH11, we retrospectively evaluated 88 patients who underwent allogeneic hematopoietic stem cell transplantation (Allo-HSCT, n = 60) or autologous HSCT (Auto-HSCT, n = 28). The D816V KIT mutation was significantly associated with post-transplant relapse, contrasting with other types of mutations in KIT. Pre- and post-transplant (3 months after transplant) CBFB-MYH11 MRD assessments were useful in predicting post-transplant relapse and poor survival. The optimal threshold was determined as a 2 log reduction at both time points. In multivariate analysis, the D816V KIT mutation and CBFB-MYH11 MRD assessments were independently associated with post-transplant relapse and survival. Stratification by D816V KIT and pre-transplant CBFB-MYH11 MRD status further distinguished the risk of relapse and survival. Auto-HSCT was superior to Allo-HSCT in MRD negative patients without D816V KIT, while Allo-HSCT trended to be superior to Auto-HSCT in patients with MRD positivity or the D816V KIT mutation. In conclusion, this study demonstrated the differentiated prognostic value of the D816V KIT mutation in AML with CBFB-MYH11 and clarified optimal time points and thresholds for CBFB-MYH11 MRD monitoring in the setting of HSCT.
Given the controversies in the prognostic value of KIT mutations and optimal thresholds and time points of MRD monitoring for AML with CBFB-MYH11, we retrospectively evaluated 88 patients who underwent allogeneic hematopoietic stem cell transplantation (Allo-HSCT, n = 60) or autologous HSCT (Auto-HSCT, n = 28). The D816V KIT mutation was significantly associated with post-transplant relapse, contrasting with other types of mutations in KIT. Pre- and post-transplant (3 months after transplant) CBFB-MYH11 MRD assessments were useful in predicting post-transplant relapse and poor survival. The optimal threshold was determined as a 2 log reduction at both time points. In multivariate analysis, the D816V KIT mutation and CBFB-MYH11 MRD assessments were independently associated with post-transplant relapse and survival. Stratification by D816V KIT and pre-transplant CBFB-MYH11 MRD status further distinguished the risk of relapse and survival. Auto-HSCT was superior to Allo-HSCT in MRD negative patients without D816V KIT, while Allo-HSCT trended to be superior to Auto-HSCT in patients with MRD positivity or the D816V KIT mutation. In conclusion, this study demonstrated the differentiated prognostic value of the D816V KIT mutation in AML with CBFB-MYH11 and clarified optimal time points and thresholds for CBFB-MYH11 MRD monitoring in the setting of HSCT.Given the controversies in the prognostic value of KIT mutations and optimal thresholds and time points of MRD monitoring for AML with CBFB-MYH11, we retrospectively evaluated 88 patients who underwent allogeneic hematopoietic stem cell transplantation (Allo-HSCT, n = 60) or autologous HSCT (Auto-HSCT, n = 28). The D816V KIT mutation was significantly associated with post-transplant relapse, contrasting with other types of mutations in KIT. Pre- and post-transplant (3 months after transplant) CBFB-MYH11 MRD assessments were useful in predicting post-transplant relapse and poor survival. The optimal threshold was determined as a 2 log reduction at both time points. In multivariate analysis, the D816V KIT mutation and CBFB-MYH11 MRD assessments were independently associated with post-transplant relapse and survival. Stratification by D816V KIT and pre-transplant CBFB-MYH11 MRD status further distinguished the risk of relapse and survival. Auto-HSCT was superior to Allo-HSCT in MRD negative patients without D816V KIT, while Allo-HSCT trended to be superior to Auto-HSCT in patients with MRD positivity or the D816V KIT mutation. In conclusion, this study demonstrated the differentiated prognostic value of the D816V KIT mutation in AML with CBFB-MYH11 and clarified optimal time points and thresholds for CBFB-MYH11 MRD monitoring in the setting of HSCT.
Given the controversies in the prognostic value of KIT mutations and optimal thresholds and time points of MRD monitoring for AML with CBFB-MYH11 , we retrospectively evaluated 88 patients who underwent allogeneic hematopoietic stem cell transplantation (Allo-HSCT, n  = 60) or autologous HSCT (Auto-HSCT, n  = 28). The D816V KIT mutation was significantly associated with post-transplant relapse, contrasting with other types of mutations in KIT . Pre- and post-transplant (3 months after transplant) CBFB-MYH11 MRD assessments were useful in predicting post-transplant relapse and poor survival. The optimal threshold was determined as a 2 log reduction at both time points. In multivariate analysis, the D816V KIT mutation and CBFB-MYH11 MRD assessments were independently associated with post-transplant relapse and survival. Stratification by D816V KIT and pre-transplant CBFB-MYH11 MRD status further distinguished the risk of relapse and survival. Auto-HSCT was superior to Allo-HSCT in MRD negative patients without D816V KIT , while Allo-HSCT trended to be superior to Auto-HSCT in patients with MRD positivity or the D816V KIT mutation. In conclusion, this study demonstrated the differentiated prognostic value of the D816V KIT mutation in AML with CBFB-MYH11 and clarified optimal time points and thresholds for CBFB-MYH11 MRD monitoring in the setting of HSCT.
Audience Academic
Author Cho, Seok-Goo
Kim, Dong-Wook
Park, Silvia
Yahng, Seung-Ah
Eom, Ki-Seong
Shin, Seung-Hwan
Kim, Yonggoo
Cho, Byung-Sik
Min, Chang-Ki
Lee, Seok
Kim, Myungshin
Kim, Yoo-Jin
Lee, Jong Wook
Lee, Sung-Eun
Park, Sung-Soo
Kim, Hee-Je
Yoon, Jae-Ho
Min, Gi-June
Jeon, Young-Woo
Author_xml – sequence: 1
  givenname: Byung-Sik
  orcidid: 0000-0002-4524-6616
  surname: Cho
  fullname: Cho, Byung-Sik
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 2
  givenname: Gi-June
  surname: Min
  fullname: Min, Gi-June
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 3
  givenname: Sung-Soo
  surname: Park
  fullname: Park, Sung-Soo
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 4
  givenname: Silvia
  surname: Park
  fullname: Park, Silvia
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 5
  givenname: Young-Woo
  orcidid: 0000-0003-3362-8200
  surname: Jeon
  fullname: Jeon, Young-Woo
  organization: Department of Hematology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 6
  givenname: Seung-Hwan
  surname: Shin
  fullname: Shin, Seung-Hwan
  organization: Department of Hematology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 7
  givenname: Seung-Ah
  surname: Yahng
  fullname: Yahng, Seung-Ah
  organization: Department of Hematology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 8
  givenname: Jae-Ho
  surname: Yoon
  fullname: Yoon, Jae-Ho
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 9
  givenname: Sung-Eun
  surname: Lee
  fullname: Lee, Sung-Eun
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 10
  givenname: Ki-Seong
  surname: Eom
  fullname: Eom, Ki-Seong
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 11
  givenname: Yoo-Jin
  surname: Kim
  fullname: Kim, Yoo-Jin
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 12
  givenname: Seok
  orcidid: 0000-0002-9442-9814
  surname: Lee
  fullname: Lee, Seok
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 13
  givenname: Chang-Ki
  surname: Min
  fullname: Min, Chang-Ki
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 14
  givenname: Seok-Goo
  orcidid: 0000-0002-5429-4839
  surname: Cho
  fullname: Cho, Seok-Goo
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 15
  givenname: Dong-Wook
  orcidid: 0000-0003-3967-4267
  surname: Kim
  fullname: Kim, Dong-Wook
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
– sequence: 16
  givenname: Jong Wook
  orcidid: 0000-0003-2949-4166
  surname: Lee
  fullname: Lee, Jong Wook
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 17
  givenname: Myungshin
  orcidid: 0000-0001-8632-0168
  surname: Kim
  fullname: Kim, Myungshin
  organization: Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 18
  givenname: Yonggoo
  surname: Kim
  fullname: Kim, Yonggoo
  organization: Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea
– sequence: 19
  givenname: Hee-Je
  orcidid: 0000-0003-4098-3366
  surname: Kim
  fullname: Kim, Hee-Je
  email: cumckim@catholic.ac.kr
  organization: Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Leukemia Research Institute, College of Medicine, The Catholic University of Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34183780$$D View this record in MEDLINE/PubMed
BookMark eNp9kltrFDEYhoNU7Lb6B7yQgCDeTE0mmUzmst3aA7YoUgWvQjbzzW7qTLJNMi696l8361Z7QEouAuF5wnd4d9CW8w4Qek3JHiVMfoicctIUpKQFoUzyYvUMTSivRVExUW2hCSmFLBgTzTbaifGSEMo5qV6gbcapZLUkE3TzJfi58zFZg3_pfoSIfYcPJRXf8afTCzyMSSfrHdauxUsItkhBu7jstUt4enB0UJz_OKEUn389xIN3Nvlg3RyvBTMmwMM19N62uIfxJwxW45VNi3viS_S8032EV7f3Lvp29PFielKcfT4-ne6fFYbXLBWs0l0LAMxQykoOpWBEG13q0gBpZrplpGsrI1sJjZxJ0tGWcFM3dQ0CmJixXfR-8-8y-KvcZVKDjQb63Af4Maqy4qJqZFXXGX37CL30Y3C5ukw1VArWMHFHzXUPyrrO58GY9adqX0hKZC3qKlN7_6HyafMwTF5nZ_P7A-HdPWEBuk-L6PtxvYP4EHxzW-U4G6BVy2AHHa7V39VmoNwAJvgYA3T_EErUOj9qkx-V86P-5EetsiQfScZuApDrtv3TKtuocbmOAIS7sT1h_QY6MNXe
CitedBy_id crossref_primary_10_1186_s13045_021_01159_2
crossref_primary_10_1038_s41409_024_02255_w
crossref_primary_10_1111_bjh_18765
Cites_doi 10.1016/j.blre.2019.05.002
10.1038/bcj.2015.116
10.1038/s41375-018-0129-6
10.1038/ng.3709
10.1158/1078-0432.CCR-18-1897
10.1182/blood-2012-06-435669
10.1182/blood-2017-09-801498
10.1200/JCO.2005.15.610
10.1038/s41375-019-0697-0
10.1016/j.bbmt.2008.08.012
10.1182/blood-2016-08-733196
10.1038/bmt.2014.180
10.1200/JCO.2007.15.3106
10.1371/journal.pone.0146614
10.1182/blood-2012-10-462879
10.1038/s41409-019-0762-3
10.1007/s00277-019-03624-y
10.1007/s00277-012-1580-5
10.1111/bjh.14340
10.1182/blood-2014-03-563403
10.1182/blood-2008-03-145862
10.1016/j.bbmt.2017.01.070
10.1002/ajh.24000
10.1182/blood-2015-12-688705
10.1007/s00277-018-3480-9
10.1200/JCO.2004.03.012
10.1182/bloodadvances.2019000709
10.1111/bjh.16745
10.3109/10428194.2015.1032964
10.1038/sj.leu.2404188
10.3390/jcm9010039
10.3390/cancers13020336
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Nature Limited 2021
2021. The Author(s), under exclusive licence to Springer Nature Limited.
COPYRIGHT 2021 Nature Publishing Group
The Author(s), under exclusive licence to Springer Nature Limited 2021.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Nature Limited 2021
– notice: 2021. The Author(s), under exclusive licence to Springer Nature Limited.
– notice: COPYRIGHT 2021 Nature Publishing Group
– notice: The Author(s), under exclusive licence to Springer Nature Limited 2021.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QO
7QP
7T5
7U9
7X7
7XB
88E
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7N
M7P
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1038/s41409-021-01384-w
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Central Student

MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1476-5365
EndPage 2689
ExternalDocumentID A681087675
34183780
10_1038_s41409_021_01384_w
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations South Korea
GeographicLocations_xml – name: South Korea
GrantInformation_xml – fundername: Korea Health Industry Development Institute (KHIDI)
  grantid: HI18C0480
  funderid: https://doi.org/10.13039/501100003710
– fundername: National Research Foundation of Korea (NRF)
  grantid: 2018R1D1A1B07043395
  funderid: https://doi.org/10.13039/501100003725
GroupedDBID ---
-Q-
.55
.XZ
0R~
23N
2WC
36B
39C
3V.
4.4
406
53G
5GY
5RE
6J9
70F
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAYZH
AAZLF
ABAKF
ABAWZ
ABDBF
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACIWK
ACKTT
ACMJI
ACPRK
ACRQY
ACUHS
ACZOJ
ADBBV
ADFRT
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFFNX
AFKRA
AFRAH
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CCPQU
CS3
DIK
DNIVK
DPUIP
DU5
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
EX3
F5P
FDQFY
FEDTE
FERAY
FIGPU
FIZPM
FRP
FSGXE
FYUFA
GX1
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IH2
IHR
IHW
INH
INR
ITC
IWAJR
J5H
JSO
JZLTJ
KQ8
LGEZI
LOTEE
M1P
M7P
N9A
NADUK
NAO
NQJWS
NXXTH
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
ROL
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UDS
UKHRP
X7M
ZGI
ZXP
~8M
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
AEIIB
PMFND
7QO
7QP
7T5
7U9
7XB
8FD
8FE
8FH
8FK
ABRTQ
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
LK8
M7N
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-c473t-35afdeee3c11324e2630aca2a2ce09bad30fd5c8d8e98b80f1d04c7977e6e36b3
IEDL.DBID 7X7
ISSN 0268-3369
1476-5365
IngestDate Fri Sep 05 07:04:12 EDT 2025
Fri Jul 25 09:02:20 EDT 2025
Tue Jun 17 21:17:39 EDT 2025
Tue Jun 10 20:47:23 EDT 2025
Thu May 22 21:26:05 EDT 2025
Thu Apr 03 06:57:31 EDT 2025
Tue Jul 01 03:21:56 EDT 2025
Thu Apr 24 22:50:45 EDT 2025
Fri Feb 21 02:40:21 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License 2021. The Author(s), under exclusive licence to Springer Nature Limited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c473t-35afdeee3c11324e2630aca2a2ce09bad30fd5c8d8e98b80f1d04c7977e6e36b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3967-4267
0000-0002-5429-4839
0000-0002-9442-9814
0000-0002-4524-6616
0000-0001-8632-0168
0000-0003-4098-3366
0000-0003-2949-4166
0000-0003-3362-8200
PMID 34183780
PQID 2591863936
PQPubID 36075
PageCount 8
ParticipantIDs proquest_miscellaneous_2546598577
proquest_journals_2591863936
gale_infotracmisc_A681087675
gale_infotracacademiconefile_A681087675
gale_healthsolutions_A681087675
pubmed_primary_34183780
crossref_primary_10_1038_s41409_021_01384_w
crossref_citationtrail_10_1038_s41409_021_01384_w
springer_journals_10_1038_s41409_021_01384_w
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-11-01
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationSubtitle Official journal of the European Society for Blood and Marrow Transplantation
PublicationTitle Bone marrow transplantation (Basingstoke)
PublicationTitleAbbrev Bone Marrow Transplant
PublicationTitleAlternate Bone Marrow Transplant
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Gorin, Labopin, Frassoni, Milpied, Attal, Blaise (CR16) 2008; 26
Nakasone, Izutsu, Wakita, Yamaguchi, Muramatsu-Kida, Usuki (CR17) 2008; 14
Kim, Ahn, Jung, Moon, Park, Lee (CR25) 2013; 92
Xiaosu, Leqing, Yazhen, Yu, Xiaohui, Lanping (CR14) 2019; 98
Boissel, Leroy, Brethon, Philippe, de Botton, Auvrignon (CR23) 2006; 20
Ishikawa, Kawashima, Atsuta, Sugiura, Sawa, Dobashi (CR6) 2020; 4
Duployez, Marceau-Renaut, Boissel, Petit, Bucci, Geffroy (CR7) 2016; 127
Yu, Yin, Wu, Jiang, Zheng, Xu (CR24) 2019; 42
Schuurhuis, Heuser, Freeman, Bene, Buccisano, Cloos (CR12) 2018; 131
Yin, O’Brien, Hills, Daly, Wheatley, Burnett (CR9) 2012; 120
Tarlock, Alonzo, Wang, Gerbing, Ries, Loken (CR26) 2019; 25
Sula, Bacher, Oppliger Leibundgut, Mansouri Taleghani, Novak, Pabst (CR30) 2020; 55
CR11
Shin, Min, Min, Cheong, Lee, Kim (CR19) 2019; 98
CR32
Qin, Xu, Chen, Jiang, Wang, Jiang (CR27) 2015; 56
Opatz, Bamopoulos, Metzeler, Herold, Ksienzyk, Braundl (CR8) 2020; 34
Hansrivijit, Gale, Barrett, Ciurea (CR31) 2019; 37
Tang, Xu, Zhang, Chen, Chen, Han (CR13) 2018; 180
Yoon, Kim, Kim, Jeon, Shin, Lee (CR20) 2014; 49
Paschka, Schlenk, Weber, Benner, Bullinger, Heuser (CR33) 2018; 32
Chen, Xie, Wang, Chen, Sun, Chen (CR10) 2016; 11
Kuwatsuka, Miyamura, Suzuki, Kasai, Maruta, Ogawa (CR18) 2009; 113
Schlenk, Benner, Krauter, Buchner, Sauerland, Ehninger (CR4) 2004; 22
Mosna, Papayannidis, Martinelli, Di Bona, Bonalumi, Tecchio (CR5) 2015; 90
Yoon, Kim, Park, Jeon, Lee, Cho (CR21) 2017; 23
Jang, Yoon, Park, Lee, Kim, Kwon (CR22) 2016; 6
Dohner, Estey, Grimwade, Amadori, Appelbaum, Buchner (CR1) 2017; 129
Wang, Wu, Liu, Qin, Wang, Xu (CR28) 2014; 124
Faber, Chen, Gedman, Boggs, Cheng, Ma (CR29) 2016; 48
Marcucci, Mrozek, Ruppert, Maharry, Kolitz, Moore (CR3) 2005; 23
Duan, Liu, Jia, Wang, Gong, Jiang (CR15) 2021; 192
Jourdan, Boissel, Chevret, Delabesse, Renneville, Cornillet (CR2) 2013; 121
JH Yoon (1384_CR21) 2017; 23
N Duployez (1384_CR7) 2016; 127
P Paschka (1384_CR33) 2018; 32
Z Xiaosu (1384_CR14) 2019; 98
NC Gorin (1384_CR16) 2008; 26
Y Kuwatsuka (1384_CR18) 2009; 113
RF Schlenk (1384_CR4) 2004; 22
JH Yoon (1384_CR20) 2014; 49
GJ Schuurhuis (1384_CR12) 2018; 131
FF Tang (1384_CR13) 2018; 180
W Duan (1384_CR15) 2021; 192
YZ Qin (1384_CR27) 2015; 56
Y Ishikawa (1384_CR6) 2020; 4
JA Yin (1384_CR9) 2012; 120
Y Wang (1384_CR28) 2014; 124
ZJ Faber (1384_CR29) 2016; 48
1384_CR32
G Yu (1384_CR24) 2019; 42
F Mosna (1384_CR5) 2015; 90
K Tarlock (1384_CR26) 2019; 25
H Dohner (1384_CR1) 2017; 129
G Marcucci (1384_CR3) 2005; 23
W Jang (1384_CR22) 2016; 6
E Jourdan (1384_CR2) 2013; 121
W Chen (1384_CR10) 2016; 11
HJ Kim (1384_CR25) 2013; 92
M Sula (1384_CR30) 2020; 55
HJ Shin (1384_CR19) 2019; 98
1384_CR11
H Nakasone (1384_CR17) 2008; 14
S Opatz (1384_CR8) 2020; 34
N Boissel (1384_CR23) 2006; 20
P Hansrivijit (1384_CR31) 2019; 37
References_xml – volume: 37
  start-page: 100578
  year: 2019
  ident: CR31
  article-title: Cellular therapy for acute myeloid Leukemia - current status and future prospects
  publication-title: Blood Rev
  doi: 10.1016/j.blre.2019.05.002
– volume: 6
  start-page: e387
  year: 2016
  ident: CR22
  article-title: Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia
  publication-title: Blood Cancer J
  doi: 10.1038/bcj.2015.116
– volume: 42
  start-page: 2333
  year: 2019
  end-page: 44
  ident: CR24
  article-title: Gene mutation profile and risk stratification in AML1ETOpositive acute myeloid leukemia based on nextgeneration sequencing
  publication-title: Oncol Rep
– volume: 32
  start-page: 1621
  year: 2018
  end-page: 30
  ident: CR33
  article-title: Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial
  publication-title: Leukemia.
  doi: 10.1038/s41375-018-0129-6
– volume: 48
  start-page: 1551
  year: 2016
  end-page: 56
  ident: CR29
  article-title: The genomic landscape of core-binding factor acute myeloid leukemias
  publication-title: Nat Genet
  doi: 10.1038/ng.3709
– volume: 25
  start-page: 5038
  year: 2019
  end-page: 48
  ident: CR26
  article-title: Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1897
– volume: 120
  start-page: 2826
  year: 2012
  end-page: 35
  ident: CR9
  article-title: Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
  publication-title: Blood.
  doi: 10.1182/blood-2012-06-435669
– volume: 131
  start-page: 1275
  year: 2018
  end-page: 91
  ident: CR12
  article-title: Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
  publication-title: Blood.
  doi: 10.1182/blood-2017-09-801498
– volume: 23
  start-page: 5705
  year: 2005
  end-page: 17
  ident: CR3
  article-title: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.15.610
– volume: 34
  start-page: 1553
  year: 2020
  end-page: 62
  ident: CR8
  article-title: The clinical mutatome of core binding factor leukemia
  publication-title: Leukemia.
  doi: 10.1038/s41375-019-0697-0
– volume: 14
  start-page: 1262
  year: 2008
  end-page: 9
  ident: CR17
  article-title: Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia
  publication-title: Biol Blood Marrow Transpl
  doi: 10.1016/j.bbmt.2008.08.012
– volume: 129
  start-page: 424
  year: 2017
  end-page: 47
  ident: CR1
  article-title: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
  publication-title: Blood.
  doi: 10.1182/blood-2016-08-733196
– volume: 49
  start-page: 1466
  year: 2014
  end-page: 74
  ident: CR20
  article-title: Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation
  publication-title: Bone Marrow Transpl
  doi: 10.1038/bmt.2014.180
– volume: 26
  start-page: 3183
  year: 2008
  end-page: 8
  ident: CR16
  article-title: Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.15.3106
– volume: 11
  start-page: e0146614
  year: 2016
  ident: CR10
  article-title: Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0146614
– volume: 121
  start-page: 2213
  year: 2013
  end-page: 23
  ident: CR2
  article-title: Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
  publication-title: Blood.
  doi: 10.1182/blood-2012-10-462879
– volume: 55
  start-page: 1690
  year: 2020
  end-page: 93
  ident: CR30
  article-title: Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia
  publication-title: Bone Marrow Transpl
  doi: 10.1038/s41409-019-0762-3
– volume: 98
  start-page: 1135
  year: 2019
  end-page: 47
  ident: CR19
  article-title: Different prognostic effects of core-binding factor positive AML with Korean AML registry data
  publication-title: Ann Hematol
  doi: 10.1007/s00277-019-03624-y
– volume: 92
  start-page: 163
  year: 2013
  end-page: 71
  ident: CR25
  article-title: KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement
  publication-title: Ann Hematol
  doi: 10.1007/s00277-012-1580-5
– volume: 180
  start-page: 448
  year: 2018
  end-page: 51
  ident: CR13
  article-title: Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia
  publication-title: Br J Haematol
  doi: 10.1111/bjh.14340
– volume: 124
  start-page: 1880
  year: 2014
  end-page: 6
  ident: CR28
  article-title: In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification
  publication-title: Blood.
  doi: 10.1182/blood-2014-03-563403
– volume: 113
  start-page: 2096
  year: 2009
  end-page: 103
  ident: CR18
  article-title: Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
  publication-title: Blood.
  doi: 10.1182/blood-2008-03-145862
– volume: 23
  start-page: 588
  year: 2017
  end-page: 97
  ident: CR21
  article-title: Clinical outcome of autologous hematopoietic cell transplantation in adult patients with acute myeloid leukemia: who may benefit from autologous hematopoietic cell transplantation?
  publication-title: Biol Blood Marrow Transpl
  doi: 10.1016/j.bbmt.2017.01.070
– volume: 90
  start-page: 515
  year: 2015
  end-page: 23
  ident: CR5
  article-title: Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up
  publication-title: Am J Hematol
  doi: 10.1002/ajh.24000
– volume: 127
  start-page: 2451
  year: 2016
  end-page: 9
  ident: CR7
  article-title: Comprehensive mutational profiling of core binding factor acute myeloid leukemia
  publication-title: Blood.
  doi: 10.1182/blood-2015-12-688705
– ident: CR11
– ident: CR32
– volume: 98
  start-page: 73
  year: 2019
  end-page: 81
  ident: CR14
  article-title: Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFbeta/MYH11 gene expression
  publication-title: Ann Hematol
  doi: 10.1007/s00277-018-3480-9
– volume: 22
  start-page: 3741
  year: 2004
  end-page: 50
  ident: CR4
  article-title: Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.03.012
– volume: 4
  start-page: 66
  year: 2020
  end-page: 75
  ident: CR6
  article-title: Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2019000709
– volume: 192
  start-page: 265
  year: 2021
  end-page: 71
  ident: CR15
  article-title: The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis
  publication-title: Br J Haematol
  doi: 10.1111/bjh.16745
– volume: 56
  start-page: 3116
  year: 2015
  end-page: 23
  ident: CR27
  article-title: Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2015.1032964
– volume: 20
  start-page: 965
  year: 2006
  end-page: 70
  ident: CR23
  article-title: Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
  publication-title: Leukemia.
  doi: 10.1038/sj.leu.2404188
– volume: 34
  start-page: 1553
  year: 2020
  ident: 1384_CR8
  publication-title: Leukemia.
  doi: 10.1038/s41375-019-0697-0
– volume: 192
  start-page: 265
  year: 2021
  ident: 1384_CR15
  publication-title: Br J Haematol
  doi: 10.1111/bjh.16745
– volume: 32
  start-page: 1621
  year: 2018
  ident: 1384_CR33
  publication-title: Leukemia.
  doi: 10.1038/s41375-018-0129-6
– volume: 120
  start-page: 2826
  year: 2012
  ident: 1384_CR9
  publication-title: Blood.
  doi: 10.1182/blood-2012-06-435669
– volume: 37
  start-page: 100578
  year: 2019
  ident: 1384_CR31
  publication-title: Blood Rev
  doi: 10.1016/j.blre.2019.05.002
– volume: 98
  start-page: 1135
  year: 2019
  ident: 1384_CR19
  publication-title: Ann Hematol
  doi: 10.1007/s00277-019-03624-y
– ident: 1384_CR32
  doi: 10.3390/jcm9010039
– volume: 56
  start-page: 3116
  year: 2015
  ident: 1384_CR27
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2015.1032964
– volume: 42
  start-page: 2333
  year: 2019
  ident: 1384_CR24
  publication-title: Oncol Rep
– volume: 121
  start-page: 2213
  year: 2013
  ident: 1384_CR2
  publication-title: Blood.
  doi: 10.1182/blood-2012-10-462879
– volume: 6
  start-page: e387
  year: 2016
  ident: 1384_CR22
  publication-title: Blood Cancer J
  doi: 10.1038/bcj.2015.116
– volume: 26
  start-page: 3183
  year: 2008
  ident: 1384_CR16
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.15.3106
– volume: 49
  start-page: 1466
  year: 2014
  ident: 1384_CR20
  publication-title: Bone Marrow Transpl
  doi: 10.1038/bmt.2014.180
– volume: 180
  start-page: 448
  year: 2018
  ident: 1384_CR13
  publication-title: Br J Haematol
  doi: 10.1111/bjh.14340
– volume: 4
  start-page: 66
  year: 2020
  ident: 1384_CR6
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2019000709
– volume: 98
  start-page: 73
  year: 2019
  ident: 1384_CR14
  publication-title: Ann Hematol
  doi: 10.1007/s00277-018-3480-9
– volume: 92
  start-page: 163
  year: 2013
  ident: 1384_CR25
  publication-title: Ann Hematol
  doi: 10.1007/s00277-012-1580-5
– volume: 11
  start-page: e0146614
  year: 2016
  ident: 1384_CR10
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0146614
– volume: 14
  start-page: 1262
  year: 2008
  ident: 1384_CR17
  publication-title: Biol Blood Marrow Transpl
  doi: 10.1016/j.bbmt.2008.08.012
– volume: 127
  start-page: 2451
  year: 2016
  ident: 1384_CR7
  publication-title: Blood.
  doi: 10.1182/blood-2015-12-688705
– ident: 1384_CR11
  doi: 10.3390/cancers13020336
– volume: 48
  start-page: 1551
  year: 2016
  ident: 1384_CR29
  publication-title: Nat Genet
  doi: 10.1038/ng.3709
– volume: 22
  start-page: 3741
  year: 2004
  ident: 1384_CR4
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.03.012
– volume: 129
  start-page: 424
  year: 2017
  ident: 1384_CR1
  publication-title: Blood.
  doi: 10.1182/blood-2016-08-733196
– volume: 25
  start-page: 5038
  year: 2019
  ident: 1384_CR26
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1897
– volume: 90
  start-page: 515
  year: 2015
  ident: 1384_CR5
  publication-title: Am J Hematol
  doi: 10.1002/ajh.24000
– volume: 23
  start-page: 588
  year: 2017
  ident: 1384_CR21
  publication-title: Biol Blood Marrow Transpl
  doi: 10.1016/j.bbmt.2017.01.070
– volume: 55
  start-page: 1690
  year: 2020
  ident: 1384_CR30
  publication-title: Bone Marrow Transpl
  doi: 10.1038/s41409-019-0762-3
– volume: 23
  start-page: 5705
  year: 2005
  ident: 1384_CR3
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.15.610
– volume: 20
  start-page: 965
  year: 2006
  ident: 1384_CR23
  publication-title: Leukemia.
  doi: 10.1038/sj.leu.2404188
– volume: 131
  start-page: 1275
  year: 2018
  ident: 1384_CR12
  publication-title: Blood.
  doi: 10.1182/blood-2017-09-801498
– volume: 113
  start-page: 2096
  year: 2009
  ident: 1384_CR18
  publication-title: Blood.
  doi: 10.1182/blood-2008-03-145862
– volume: 124
  start-page: 1880
  year: 2014
  ident: 1384_CR28
  publication-title: Blood.
  doi: 10.1182/blood-2014-03-563403
SSID ssj0014405
Score 2.372959
Snippet Given the controversies in the prognostic value of KIT mutations and optimal thresholds and time points of MRD monitoring for AML with CBFB-MYH11 , we...
Given the controversies in the prognostic value of KIT mutations and optimal thresholds and time points of MRD monitoring for AML with CBFB-MYH11, we...
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2682
SubjectTerms 45/23
45/77
631/208/69
631/67/1990/283/1897
692/308/575
692/699/1541/1990/283/1897
Acute myeloid leukemia
Assessments
Autografts
Cell Biology
Core Binding Factor beta Subunit - genetics
Gene mutations
Health aspects
Hematology
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Internal Medicine
Leukemia
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - therapy
Medicine
Medicine & Public Health
Monitoring
Multivariate analysis
Mutation
Myeloid leukemia
Myosin Heavy Chains - genetics
Neoplasm, Residual - diagnosis
Neoplasm, Residual - genetics
Prognosis
Public Health
Retrospective Studies
Stem cell transplantation
Stem Cells
Survival
Thresholds
Transplantation
Transplants & implants
Title Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11
URI https://link.springer.com/article/10.1038/s41409-021-01384-w
https://www.ncbi.nlm.nih.gov/pubmed/34183780
https://www.proquest.com/docview/2591863936
https://www.proquest.com/docview/2546598577
Volume 56
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY9_z2nUaDPawicqWbMtPo2ka0pWUUtqRPQlLOkNZYreNQ9nT_vXpbMdtCuuj0cm2dHfS6U73O0I-e6M75LbgzGGeslTGsIyDY0ZlUWyszdoM78lxMj6XP6bxtHO4Lbprlas1sVmoXWXRR77rzfRQ-e1UJN8vrxhWjcLoaldC4zHZDL0lgqUb0ml_4MK4Zdz6WBQTIsm6pBku1O5CItITwwsKGKuT7GZtY7q_PN_Zn-4FTJt9aPScPOsMSLrXcvwFeQTlS_Jk0oXIX5G_J9cVXp7zzRSRvGFBq4IOVZj8pEeHZ3S-bIPvNC8dRZhjVjf45jM_xXR_MBqwya9xGNLJ6ZDOG4XH_6DYwS5roPM_MKsuHJ3B8jfML3KKntw7HV-T89HB2f6YdVUWmJWpqJmI88IBgLBYdF5ClAie2zzKIws8M7kTvHCxVU5BpoziRei4tKm3GyEBkRjxhmyUVQnvCJVRkQJksfV2iRQSjDGFsHmYxMKf05wNSLiaYm07CHKshDHTTShcKN2yRXu26IYt-iYgX_s-ly0Ax4PUH5Fzuk0i7bVX7yHsmkLgmoB8aShQf_23bd6lIfgRIBLWGuX2GqXXO7vevJIO3en9Qt9KaUA-9c3YE--ylVAtkUYmcabiNA3I21aq-pF5mwIR_nlAvq3E7Pbl_x_2-4f_ZYs8jVDSmxTKbbJRXy_hg7elarPTKMwO2RwcHJ-c-qfh4dE_En8YjA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwEviG8CgxkJxANYS2IndR4mtK6rWrpW09Sh8WRi-yJNtM1YW1V74j_jb8OXj26dxN727LMT5853F9_d7wj54JzuwDeZzyzWKQupNUt8sEzLJIy0MUlZ4T0Yxt0T8e00Ot0gf-taGEyrrHVioahtbvCOfMe56YF05pTHX89_M-wahdHVuoVGWrVWsLsFxFhV2NGHy6X7hZvt9tqO3x_DsHMw2u-yqssAM6LJ54xHaWYBgBtsui4gjLmfmjRMQwN-olPL_cxGRloJidTSzwLrC9N0fhPEwGPN3br3yKbAC5QG2WwdDI-OV3EMIcokyjCWjPM4qcp2fC53ZgKxphimSGC0ULDlmmm8aSCuWcgbIdvCEnYek0eVC0v3Spl7QjZg-pTcH1RB-mfkz9FFjul7bpgiljjMaJ7Rtgzi77TfG9HJogz_03RqKQIts3mBsD52TKb7rU6LDX50g4AOjtt0UqgcfA-KE8xiDnRyCeP8zNIxLH7B5CyleJd8beJzcnInHHhBGtN8Cq8IFWHWBEgi4zwjwQVorTNu0iCOuPtTtMYjQf2JlalA0LEXx1gVwXguVckW5diiCraopUc-r-aclxAgt1JvI-dUWca60h9qD4HfJELneORTQYEaxD3bpFUhhNsBYnGtUW6tUbqTb9aHa-lQleaZqatz4pH3q2Gcidl0U8gXSCPiKJFRs-mRl6VUrXbmvBrsMeB75EstZleL_3_br29_l23yoDsaHKrD3rD_hjwMUeqLgs4t0phfLOCt8-zm-l11fCj5edcn9h88H1sH
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1Nb9Mw1BpDmrggvgkMZiQQB7CaxE7iHBDaVqqW0mlCG-pOJrZfpIk2GWuraif-F78Ov3x06yR229nPTuz3ab8vQt46ozvwTe4zi3nKQmrNUh8s0zINI21MWmd4jw7i_rH4Oo7GG-RvmwuDYZWtTKwEtS0NvpF3nJkeSKdOedzJm7CIw27v89lvhh2k0NPattOoSWQIF0t3fZt9GnQdrt-FYe_L0X6fNR0GmBEJnzMeZbkFAG6w4bqAMOZ-ZrIwCw34qc4s93MbGWklpFJLPw-sL0zibCaIgceau3XvkLsJFwLbRiTj1WUPfaZR_b4jGedx2iTs-Fx2ZgKrTDEMjkA_oWDLNaV4XTVc0Y3XnLWVDuw9IPcb45Xu1tT2kGxA8YhsjRr3_GPy5_C8xMA9N0yxijjMaJnTrgziH3Q4OKLTRe34p1lhKZZYZvOqtvrEoZfu7_X22OikHwR09L1Lp5Wwwf-gOMEs5kCnFzApTy2dwOIXTE8ziq_IVyY-Ice3cv5PyWZRFvCcUBHmCUAaGWcTCS5Aa51zkwVxxN0d0RqPBO0RK9OUP8cuHBNVueG5VDValEOLqtCilh75sJpzVhf_uBF6BzGn6gTWleRQu1jyTWLRHI-8ryBQdrhvm6xJgXA7wCpca5Dba5CO5836cEsdqpE5M3XJIR55sxrGmRhHV0C5QBgRR6mMksQjz2qqWu3M2TPYXcD3yMeWzC4X__-2X9z8Lztky_Gp-jY4GL4k90Ik-iqTc5tszs8X8MqZdHP9uuIdSn7eNrP-A647WKM
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+values+of+D816V+KIT+mutation+and+peri-transplant+CBFB-MYH11+MRD+monitoring+on+acute+myeloid+leukemia+with+CBFB-MYH11&rft.jtitle=Bone+marrow+transplantation+%28Basingstoke%29&rft.au=Cho+Byung-Sik&rft.au=Gi-June%2C+Min&rft.au=Park%2C+Sung-Soo&rft.au=Park%2C+Silvia&rft.date=2021-11-01&rft.pub=Nature+Publishing+Group&rft.issn=0268-3369&rft.eissn=1476-5365&rft.volume=56&rft.issue=11&rft.spage=2682&rft.epage=2689&rft_id=info:doi/10.1038%2Fs41409-021-01384-w&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0268-3369&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0268-3369&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0268-3369&client=summon